Cost-effectiveness analysis of the SP142 versus 22C3 PD-L1 assays in the treatment of atezolizumab plus nab-paclitaxel for patients with advanced triple negative breast cancer in the Brazilian private healthcare system

Triple Negative ◽

Private Healthcare ◽

Cost-effectiveness analysis of atezolizumab in advanced triple-negative breast cancer

BMC Health Services Research ◽

10.1186/s12913-020-05445-6 ◽

2020 ◽

Vol 20 (1) ◽

Author(s):

Lee Cheng Phua ◽

Soo Chin Lee ◽

Kwong Ng ◽

Mohamed Ismail Abdul Aziz

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Triple Negative ◽

PCN151 COST-EFFECTIVENESS ANALYSIS OF ATEZOLIZUMAB FOR WOMEN WITH METASTATIC TRIPLE NEGATIVE BREAST CANCER IN FRANCE

Value in Health ◽

10.1016/j.jval.2019.09.347 ◽

2019 ◽

Vol 22 ◽

pp. S464-S465

Author(s):

A. Gherardi ◽

C. Ouared ◽

B. Tehard ◽

S. Roze

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Triple Negative ◽

Cost-effectiveness Analysis of Atezolizumab Plus Nab-Paclitaxel for Advanced PD-L1 Positive Triple-Negative Breast Cancer in Japan

Clinical Drug Investigation ◽

10.1007/s40261-021-01017-6 ◽

2021 ◽

Author(s):

Yugo Chisaki ◽

Yoshiki Kuwada ◽

Chikako Matsumura ◽

Yoshitaka Yano

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Triple Negative ◽

PCV33 COST-EFFECTIVENESS ANALYSIS OF INCORPORATING CRYO-BALLON CRYOABLATION FOR TREATMENT OF ATRIAL FIBRILLATION IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM

Value in Health ◽

10.1016/j.jval.2020.04.138 ◽

2020 ◽

Vol 23 ◽

pp. S96

Author(s):

S. Borghossian ◽

F.A. Fujii ◽

P. Moretti

Keyword(s):

Atrial Fibrillation ◽

Cost Effectiveness ◽

Healthcare System ◽

Private Healthcare ◽

PGI17 COST EFFECTIVENESS ANALYSIS OF ENDOSCOPIC CAPSULE FOR DIAGNOSIS OF OBSCURE GASTROINTESTINAL BLEEDING IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM

Value in Health ◽

10.1016/j.jval.2020.04.374 ◽

2020 ◽

Vol 23 ◽

pp. S145-S146

Author(s):

A.M. Zuccaro ◽

F.A. Fujii ◽

P. Moretti

Keyword(s):

Cost Effectiveness ◽

Gastrointestinal Bleeding ◽

Healthcare System ◽

Obscure Gastrointestinal Bleeding ◽

Private Healthcare ◽

Effectiveness Analysis ◽

Endoscopic Capsule

PCN122 COST-EFFECTIVENESS ANALYSIS OF TRASUTUZUMAB EMTANSINE VERSUS TRASTUZUMAB FOR WOMEN WITH HER2+ ADJUVANT BREAST CANCER IN FRANCE

Value in Health ◽

10.1016/j.jval.2019.09.318 ◽

2019 ◽

Vol 22 ◽

pp. S459 ◽

Cited By ~ 1

Author(s):

A. Gherardi ◽

R. Sellami ◽

B. Tehard ◽

S. Roze

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Effectiveness Analysis ◽

Adjuvant Breast Cancer

Cost-Effectiveness Analysis: Lymph Node Transfer vs Lymphovenous Bypass for Breast Cancer-Related Lymphedema

Journal of the American College of Surgeons ◽

10.1016/j.jamcollsurg.2021.02.013 ◽

2021 ◽

Author(s):

Yurie Sekigami ◽

Sydney Char ◽

Cate Mullen ◽

Kathryn Huber ◽

Yu Cao ◽

...

Keyword(s):

Breast Cancer ◽

Lymph Node ◽

Cost Effectiveness ◽

Effectiveness Analysis ◽

Breast Cancer Related Lymphedema ◽

Lymph Node Transfer

58P Cost-effectiveness analysis of trastuzumab emtansine versus trastuzumab for Chinese patients with residual invasive HER2-positive early breast cancer

Annals of Oncology ◽

10.1016/j.annonc.2021.03.072 ◽

2021 ◽

Vol 32 ◽

pp. S45

Author(s):

X. Guan ◽

H-C. Li ◽

Q-J. Chen ◽

B. Hua ◽

J-J. Li ◽

...

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Early Breast Cancer ◽

Chinese Patients ◽

Trastuzumab Emtansine ◽

Her2 Positive ◽

Cost-effectiveness analysis of trastuzumab for early breast cancer in Brazil

Expert Review of Pharmacoeconomics & Outcomes Research ◽

10.1080/14737167.2021.1909478 ◽

2021 ◽

pp. 1-10

Author(s):

Carlos Henrique Botelho ◽

Maria Del Pilar Estevez-Diz ◽

Alessandro Gonçalves Campolina

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Early Breast Cancer ◽

PCN69 Cost-Effectiveness Analysis of NOVEL Therapies for HER2+ Metastatic Breast Cancer: [FAM-] Trastuzumab Deruxtecan Versus Tucatinib Trastuzumab and Capecitabine Combination

Value in Health ◽

10.1016/j.jval.2020.08.206 ◽

2020 ◽

Vol 23 ◽

pp. S433-S434

Author(s):

G. Vondeling ◽

E. Palaka ◽

C. Livings ◽

J. Naik ◽

W. Sullivan

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Cost Effectiveness ◽

Metastatic Breast ◽

Novel Therapies ◽